Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China

BACKGROUND: As a new non-factor therapy for hemophilia A (HA), real-world study of emicizumab is still scarce. This study aimed to investigate the real-world use of emicizumab in Chinese boys with HA. METHODS: Patients with moderate or severe HA were enrolled at Beijing Children's Hospital. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Guoqing, Huang, Kun, Li, Gang, Zhen, Yingzi, Li, Zhengping, Chen, Zhenping, Wu, Runhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627604/
https://www.ncbi.nlm.nih.gov/pubmed/36340724
http://dx.doi.org/10.3389/fped.2022.992267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627604/
https://www.ncbi.nlm.nih.gov/pubmed/36340724
http://dx.doi.org/10.3389/fped.2022.992267

Ejemplares similares